Cargando…
Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
There are limited data evaluating conformation of antithrombotic therapy usage to the guideline recommendations. We investigated clinical trends and prognoses of patients with atrial fibrillation (AF) according to anticoagulants and antiplatelet agents beyond 1 year after percutaneous coronary inter...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348599/ https://www.ncbi.nlm.nih.gov/pubmed/34362151 http://dx.doi.org/10.3390/jcm10153370 |
_version_ | 1783735379183009792 |
---|---|
author | Yoon, Gwang-Seok Kim, Sun-Hwa Kang, Si-Hyuck Yoon, Chang-Hwan Cho, Young-Seok Youn, Tae-Jin Chae, In-Ho |
author_facet | Yoon, Gwang-Seok Kim, Sun-Hwa Kang, Si-Hyuck Yoon, Chang-Hwan Cho, Young-Seok Youn, Tae-Jin Chae, In-Ho |
author_sort | Yoon, Gwang-Seok |
collection | PubMed |
description | There are limited data evaluating conformation of antithrombotic therapy usage to the guideline recommendations. We investigated clinical trends and prognoses of patients with atrial fibrillation (AF) according to anticoagulants and antiplatelet agents beyond 1 year after percutaneous coronary intervention (PCI). We analyzed the records of patients with AF who underwent PCI using the Korean National Health Insurance Service database. The primary endpoint was a composite of major adverse cardiac events (MACE). The safety outcome was bleeding complications. Of 4193 participants, 81.6% received antiplatelet therapy, whereas 27.3% had oral anticoagulant (OAC)-based therapy at 18 months after PCI. The dominant therapy was dual antiplatelet therapy (37.2%), and only 3.3% of participants had OAC monotherapy. At the 1-year follow-up, the incidence of MACE was significantly lower among those receiving a combination of OAC and single antiplatelet therapy (SAPT) than among those receiving OAC monotherapy (4.78% vs. 9.42%, p = 0.017). Bleeding complication events (5.01% vs. 5.80%, p = 0.587) did not differ between the groups. In clinical practice, most patients with AF who underwent PCI continued to receive antiplatelet agents beyond 1-year post-PCI. OAC with SAPT seemed to be more effective than OAC monotherapy, without a difference in safety. |
format | Online Article Text |
id | pubmed-8348599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83485992021-08-08 Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents Yoon, Gwang-Seok Kim, Sun-Hwa Kang, Si-Hyuck Yoon, Chang-Hwan Cho, Young-Seok Youn, Tae-Jin Chae, In-Ho J Clin Med Article There are limited data evaluating conformation of antithrombotic therapy usage to the guideline recommendations. We investigated clinical trends and prognoses of patients with atrial fibrillation (AF) according to anticoagulants and antiplatelet agents beyond 1 year after percutaneous coronary intervention (PCI). We analyzed the records of patients with AF who underwent PCI using the Korean National Health Insurance Service database. The primary endpoint was a composite of major adverse cardiac events (MACE). The safety outcome was bleeding complications. Of 4193 participants, 81.6% received antiplatelet therapy, whereas 27.3% had oral anticoagulant (OAC)-based therapy at 18 months after PCI. The dominant therapy was dual antiplatelet therapy (37.2%), and only 3.3% of participants had OAC monotherapy. At the 1-year follow-up, the incidence of MACE was significantly lower among those receiving a combination of OAC and single antiplatelet therapy (SAPT) than among those receiving OAC monotherapy (4.78% vs. 9.42%, p = 0.017). Bleeding complication events (5.01% vs. 5.80%, p = 0.587) did not differ between the groups. In clinical practice, most patients with AF who underwent PCI continued to receive antiplatelet agents beyond 1-year post-PCI. OAC with SAPT seemed to be more effective than OAC monotherapy, without a difference in safety. MDPI 2021-07-29 /pmc/articles/PMC8348599/ /pubmed/34362151 http://dx.doi.org/10.3390/jcm10153370 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yoon, Gwang-Seok Kim, Sun-Hwa Kang, Si-Hyuck Yoon, Chang-Hwan Cho, Young-Seok Youn, Tae-Jin Chae, In-Ho Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents |
title | Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents |
title_full | Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents |
title_fullStr | Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents |
title_full_unstemmed | Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents |
title_short | Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents |
title_sort | prognosis of atrial fibrillation patients undergoing pci according to anticoagulants and antiplatelet agents |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348599/ https://www.ncbi.nlm.nih.gov/pubmed/34362151 http://dx.doi.org/10.3390/jcm10153370 |
work_keys_str_mv | AT yoongwangseok prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents AT kimsunhwa prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents AT kangsihyuck prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents AT yoonchanghwan prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents AT choyoungseok prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents AT yountaejin prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents AT chaeinho prognosisofatrialfibrillationpatientsundergoingpciaccordingtoanticoagulantsandantiplateletagents |